222 related articles for article (PubMed ID: 17577032)
1. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Ranson M; Hersey P; Thompson D; Beith J; McArthur GA; Haydon A; Davis ID; Kefford RF; Mortimer P; Harris PA; Baka S; Seebaran A; Sabharwal A; Watson AJ; Margison GP; Middleton MR
J Clin Oncol; 2007 Jun; 25(18):2540-5. PubMed ID: 17577032
[TBL] [Abstract][Full Text] [Related]
2. O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.
Watson AJ; Middleton MR; McGown G; Thorncroft M; Ranson M; Hersey P; McArthur G; Davis ID; Thomson D; Beith J; Haydon A; Kefford R; Lorigan P; Mortimer P; Sabharwal A; Hayward O; Margison GP
Br J Cancer; 2009 Apr; 100(8):1250-6. PubMed ID: 19367283
[TBL] [Abstract][Full Text] [Related]
3. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
Ranson M; Middleton MR; Bridgewater J; Lee SM; Dawson M; Jowle D; Halbert G; Waller S; McGrath H; Gumbrell L; McElhinney RS; Donnelly D; McMurry TB; Margison GP
Clin Cancer Res; 2006 Mar; 12(5):1577-84. PubMed ID: 16533784
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
Kaufmann R; Spieth K; Leiter U; Mauch C; von den Driesch P; Vogt T; Linse R; Tilgen W; Schadendorf D; Becker JC; Sebastian G; Krengel S; Kretschmer L; Garbe C; Dummer R;
J Clin Oncol; 2005 Dec; 23(35):9001-7. PubMed ID: 16260697
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.
Khan OA; Ranson M; Michael M; Olver I; Levitt NC; Mortimer P; Watson AJ; Margison GP; Midgley R; Middleton MR
Br J Cancer; 2008 May; 98(10):1614-8. PubMed ID: 18475294
[TBL] [Abstract][Full Text] [Related]
6. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
[TBL] [Abstract][Full Text] [Related]
7. A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
Alvino E; Castiglia D; Caporali S; Pepponi R; Caporaso P; Lacal PM; Marra G; Fischer F; Zambruno G; Bonmassar E; Jiricny J; D'Atri S
Int J Oncol; 2006 Oct; 29(4):785-97. PubMed ID: 16964376
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
[TBL] [Abstract][Full Text] [Related]
10. MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
Tuominen R; Jewell R; van den Oord JJ; Wolter P; Stierner U; Lindholm C; Hertzman Johansson C; Lindén D; Johansson H; Frostvik Stolt M; Walker C; Snowden H; Newton-Bishop J; Hansson J; Egyházi Brage S
Int J Cancer; 2015 Jun; 136(12):2844-53. PubMed ID: 25400033
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Agarwala SS; Kirkwood JM
Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.
Kefford RF; Thomas NP; Corrie PG; Palmer C; Abdi E; Kotasek D; Beith J; Ranson M; Mortimer P; Watson AJ; Margison GP; Middleton MR
Br J Cancer; 2009 Apr; 100(8):1245-9. PubMed ID: 19367282
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial.
Wierzbicka-Hainaut E; Sassolas B; Mourey L; Guillot B; Bedane C; Guillet G; Tourani JM
Melanoma Res; 2010 Apr; 20(2):141-6. PubMed ID: 20075758
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours.
Tawbi HA; Villaruz L; Tarhini A; Moschos S; Sulecki M; Viverette F; Shipe-Spotloe J; Radkowski R; Kirkwood JM
Br J Cancer; 2011 Sep; 105(6):773-7. PubMed ID: 21811257
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide and cisplatin in avdanced malignant melanoma.
Daponte A; Ascierto PA; Gravina A; Melucci M; Scala S; Ottaiano A; Simeone E; Palmieris G; Comella G
Anticancer Res; 2005; 25(2B):1441-7. PubMed ID: 15865103
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
[TBL] [Abstract][Full Text] [Related]
17. A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
Beasley GM; Speicher P; Augustine CK; Dolber PC; Peterson BL; Sharma K; Mosca PJ; Royal R; Ross M; Zager JS; Tyler DS
Ann Surg Oncol; 2015 Jan; 22(1):287-94. PubMed ID: 25145500
[TBL] [Abstract][Full Text] [Related]
18. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
Middleton MR; Lee SM; Arance A; Wood M; Thatcher N; Margison GP
Int J Cancer; 2000 Nov; 88(3):469-73. PubMed ID: 11054678
[TBL] [Abstract][Full Text] [Related]
19. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
Guillot B; Khamari A; Cupissol D; Delaunay M; Bedane C; Dreno B; Picot MC; Dereure O
Melanoma Res; 2008 Apr; 18(2):141-6. PubMed ID: 18337651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
